Research Article

Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

Table 3

Effects of liraglutide treatment on clinical characteristics and biochemical and metabolic parameters.

PretreatmentPosttreatmentChanges

Clinical characteristics
(men/women)20 (17/3)
Age (years)
Weight (kg)-4.9 (-6.1, -3.7)<0.001
BMI (kg/m2)-1.9 (-2.3, -1.5)<0.001
Waist circumference (cm)-6.1 (-7.2, -4.9)<0.001
Biochemical and metabolic parameters
FBG (mmol/L)-3.3 (-5.1, -2.0)<0.001
2 hPBG (mmol/L)-8.7 (-11.4, -5.9)<0.001
FINS (μU/ml)-0.9 (-4.6, 2.9)0.636
HOMA-IR-1.7 (-3.2, -0.24)0.024
HbA1c (%)-3.8 (-4.7, -2.9)<0.001
TCH (mmol/L)-0.8 (-1.5, -0.1)0.028
HDL (mmol/L)0.1 (-0.1, 0.1)0.172
LDL (mmol/L)0.0 (-0.4, 0.5)0.862
TG (mmol/L)-1.7 (-3.3, -0.2)0.030
ALT (U/L)-24.1 (-34.4, -13.7)<0.001
AST (U/L)-15.3 (-23.3, -7.3)<0.001
ALP (U/L)-8.9 (-18.4, 0.5)0.062
GGT (U/L)-32.4 (-59.1, -5.6)0.020
FGF21 (pg/ml)-110.7 (-185.8, -35.6)0.006
Liver fat content (%)-8.7 (-11.9, -5.5)<0.001

Abbreviations: BMI: body mass index; FBG: fasting blood glucose; 2 hPBG: 2-hour postprandial blood glucose; FINS: fasting insulin; HOMA-IR: homeostasis model assessment of insulin resistance; HbA1c: glycated hemoglobin; TC: total cholesterol; HDL: high-density lipoprotein cholesterol; TG: triglyceride; LDL: low-density lipoprotein cholesterol; ALT: alanine amino transferase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; GGT: γ-glutamyl transferase; FGF21: fibroblast growth factor 21. ; .